| Use of methotrexate in young patients with respect to the reproductive system. | |
| | |
MedLine Citation:
|
PMID: 21044438 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Methotrexate (MTX) is one of the most commonly used drugs in the treatment of inflammatory rheumatic diseases. Unfortunately, MTX is an FDA Pregnancy Category X medication, which means it is contraindicated during pregnancy. The following review of the literature, with international guidelines, gives in addition an overview of current scientific knowledge on the topic. MTX is a teratogenic substance. It accesses the placenta and, for the dosage of 5 to 25 mg per week normally used in rheumatic diseases, can lead to both habitual abortions and anomalies in the neonate. Folic acid antagonism of MTX is the reason. In the rheumatologic setting, small case reports are available for the usage of MTX of 101 pregnant women at the time of conception or during pregnancy, mostly during the first trimester. Individual casuistry also exists. An abortion rate of 23% was found to result from these case reports. The anomaly rate for neonates was >5%. Only a few pregnancies with neonatal anomalies are described with the child's father taking MTX at the time of conception. MTX is taken up (in small amounts) by the mother's milk, and breast feeding under MTX therapy, therefore, is also contraindicated. Detailed and exact information on female patients taking MTX during the reproduction phase, but also for the father-to-be of the child if treated with MTX, with reference to the required contraception until at least three months before a planned conception and stopping of MTX at least at that time, is essential. |
| | |
Authors:
|
E Gromnica-Ihle; K Krüger |
Related Documents
:
|
11826768 - Pheochromocytoma in a pregnant woman with multiple endocrine neoplasia type 2a. 11975968 - Hysteroscopic management of cornual ectopic pregnancy. 12101338 - Laparoscopic treatment of cornual heterotopic pregnancy. 22209508 - Endovascular treatment of ruptured intracranial aneurysms during pregnancy: is this the... 3812728 - Morphology and development of an apoeccrine sweat gland in human axillae. 12820448 - Updated diagnostic criteria for partial and complete hydatidiform moles in early pregna... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-10-28 |
Journal Detail:
|
Title: Clinical and experimental rheumatology Volume: 28 ISSN: 0392-856X ISO Abbreviation: Clin. Exp. Rheumatol. Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2010-11-03 Completed Date: 2010-12-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8308521 Medline TA: Clin Exp Rheumatol Country: Italy |
Other Details:
|
Languages: eng Pagination: S80-4 Citation Subset: IM |
Affiliation:
|
Rheumatology Center St. Bonifatius, Munich, Germany. erika@gromnica-ihle.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abnormalities, Drug-Induced
/
etiology* Abortion, Spontaneous / chemically induced* Age Factors Antirheumatic Agents / adverse effects*, contraindications, metabolism Breast Feeding / adverse effects Female Fertility / drug effects* Health Knowledge, Attitudes, Practice Humans Male Methotrexate / adverse effects*, contraindications, metabolism Milk, Human / metabolism Patient Education as Topic Practice Guidelines as Topic Pregnancy Rheumatic Diseases / drug therapy* Risk Assessment Risk Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotre...
Next Document: Use of MTX in the elderly and in patients with compromised renal function.